The recent discovery of the 5-lipoxygenase (5-LO) inhibitor has attracted strong research attention as it has the potential to offer a magic bullet treatment for inflammation.
1 Leukotrienes are the products of the lipoxygenase-catalyzed reaction that initiate and amplify acute inflammation.
2 These eicosanoids have potent pro-inflammatory properties, including bronchoconstriction and chemotaxis of polymorphonuclear leukocytes, and are implicated in the pathogenesis of several inflammatory diseases, most notably asthma, psoriasis, rheumatoid arthritis and inflammatory bowel disease.
3
Furthermore, as the level of leukotrienes is elevated in inflammatory diseases, their blockade increases clinical effectiveness in inflammation treatment. 4 Among three mammalian lipoxygenases (5-lipoxygenase, or 5-LO, 12-LO and 15-LO), 5-LO is the rate-limiting enzyme in leukotriene biosynthesis from arachidonic acid via production of 5-hydroperoxyeicosatetraenoic acid. Thus, inhibition of 5-LO could have therapeutic potential in a wide range of allergic and inflammatory conditions. Zileuton (Zyflo ® ), a representative 5-LO inhibitor, has demonstrated therapeutic benefit as an anti-asthmatic agent. 5 Zileuton contains a Nhydroxyurea moiety and interacts with 5-LO via coordination with the active-site iron atom. 6 The half-life of zileuton in humans was shown to be 2.4 h, which necessitates administration up to 4 times a day. Several other compounds have been reported as 5-LO inhibitors, and some were found to cause methemoglobin formation due to their redox properties.
7 Therefore, new 5-LO inhibitors need to be developed to improve the efficacy and side effect profiles.
Over several years, we have investigated many structural classes of 5-LO inhibitors with the aim of identifying orally active 5-LO inhibitors, and we discovered a new series of benzopyran derivatives as highly potent 5-LO inhibitors via screening of our in-house small molecule libraries. However, we have only managed to report the biochemical and pharmacological profiles of one representative lead compound 1 (KRH-102140) (Fig. 2) . 8 Herein, we report initial evidence showing that compounds with a 2-methyl-2-alkylsubstituted-2H-chromen-6-yl-amine core skeleton are selective 5-LO inhibitors, and present an optimization process to identify potential 5-LO anti-inflammatory agents using a pharmacophore model. First, to identify small-molecule inhibitors of 5-LO, we screened 1,200 compounds using the ferrous oxidationxylenol orange (Ed-the acronym FOX is unnecessary as it is not used anywhere else in the paper) assay, which is based on the complex formation of Fe 3+ /xylenol orange with absorption in visible light.
9 Therefore, the compounds can be tested for whether 5-LO activation is inhibited using this system. These 1,200 compounds represent structurally di- verse and druggable 20,000-member heterocyclic compound libraries, including imidazoles, benzopyrans, oxazoles, thiazoles, thiadiazoles, and pyridines.
10 The primary screening identified several 2-methyl-2-alkylsubstituted-2H-chromen-6-yl-amine derivatives ( Figure 1 , 2-9 compounds) as inhibitors of 5-LO cell activities ( Figure 1 ). From preliminary structure-activity relationship of 2-9, it appears that the 6-(2-methyl-2-phenylethyl-2H-chromen-6-yl)-amine 5 is critical to their 5-LO inhibitory activities, as shown in Figure 1 .
In the search for superior 5-LO inhibitor based on the primary hit compound 5, we studied the structure-activity relationship between our real hit compound and selected known 5-LO inhibitors (Figure 4 , R1-R5). To clearly investigate the structure-activity relationship studies of 2-9, we selected 286 known compounds from the Prous site (http://integrity.thomson-pharm.com) as 5-LO inhibitors. After the 3D structures of these compounds were generated using CONCORD, 11 they were minimized using GasteigerHuckel charges and conjugated gradient methods. In order to consider the structural redundancy of the subset, we carried out the maximum dissimilarity study using the Extended Connectivity Fingerprints (ECFP). 12 We selected 5 reference compounds as the training set, as shown in Figure 4 . Based on the bioisostere concept, we considered the selected references (especially Figure 4 , R1-R5) [13] [14] [15] [16] [17] as having quite similar core skeletons with our primary hit compound 2-methyl-2-alkylsubstituted-2H-chromen-6-yl-amine 5 structure. The common feature pharmacophores were generated using the HipHop algorithm.
18 Predefined pharmacophore features were used to automatically create the pharmaco- . From the results of the structureactivity relationship studies of 2-9 and the selected five known compounds, we decided to synthesize 6-alkyl substituted-(2-methyl-2-phenethyl-2H-chromen-6-yl)-amine derivative 1 based on 6-(2-methyl-2-phenethyl-2H-chromen-6-yl)-amine core skeleton 5, as shown in Figure 2 .
Therefore, we next synthesized 39 compounds from the second focused library, 6-alkylsubstituted-(2-methyl-2-phenethyl-2H-chromen-6-yl)-amine derivatives, via the second optimization process.
19,20 Among these compounds, three (Figure 3, 1, 13 , and 21) that had a 6-alkylsubstituted-(2-methyl-2-phenethyl-2H-chromen-6-yl)-amine derivative were selected for further pharmacological test to discover the inflammatory drug. Despite their structural similarity to the 6-alkylsubstituted-(2-methyl-2-phenethyl-2H-chromen- 6-yl)-amine derivatives, the IC 50 values significantly varied (Figure 3 ). Finally, we tested the selected hit compound 1 for various biological activities via in vitro assay of LTB 4 secretion in RBL-1 cells and in vivo assay of arachidonic acid-induced edema animal model to identify the drug-like, anti-inflammatory lead compound; we have already published this result in our previous pharmacology report. 8 We then carried out pharmacophore mapping for the final hit compound 1 with the pharmacophore model generated by the five reference compounds, as shown in Figure 4(c) , and found that the 6-alkylamino group on 2-methyl-2-phenethyl-2H-chromen structures may be important for 5-LO activity. Next, we examined the cell inhibition effect of the three selected, more active hit compounds, 1, 13 and 21, which were chosen from the first screening, on the 5-LO inhibition effect previously determined by in vitro assay. Especially, the two most active compounds, 1 and 13, showed good fit values of 3.55 and 3.77, respectively, as shown in Figure 5 .
In summary, we screened 1,200 heterocyclic small molecule libraries to identify a novel hit core skeleton of 6-(2-methyl-2-phenethyl-2H-chromen-6-yl)-amine derivatives ( Figure 1, 8 compounds) , which were selected as potential 5-LO inhibitors, and demonstrated its effects in 5-LO inhibition (Figure 3, 12 compounds) . The final three selected hit compounds (Figure 3; 1, 13 , and 21) were identified on LTB 4 secretion in RBL-1 cells in in vitro, in vivo and pharmacology analyses for the development of a novel anti-inflammatory drug underlying the 5-LO mechanistic target. Finally, the best two active compounds, 1 and 13, showed good fit values of 3.55 and 3.77, respectively, in the pharmacophore model.
After carbamate resin of formula 1-1 (200.00 mg, 0.10 mmol) in a form of 2-methyl-2-phenethyl-2H-chromen-6-amine 1-2 (5.30 mg, 0.20 mmol) was mixed with dimethylsulfoxide (DMSO, 3 mL) by shaking at room temperature for 10 min, 1 M lithium tbutoxide (LiOtBu-; 0.30 mL, 0.30 mmol) dissolved in tetrahydrofuran (THF) was added thereto and mixed by shaking at the same temperature for 20 min. 2-Fluorobenzyl chloride (2-F-BnCl; 4.32 mg, 0.30 mmol) was added thereto and the reaction mixture was shaken at 35 o C for 15 hrs. After the reaction was completed, the reaction mixture was subjected to filtration and repeatedly washed with DMF, DCM, DCM/MeOH and MeOH, to obtain a lightbrown solid resin 1-5 (202.3 mg). To a suspension of the resin 1-5 (200.00 mg, 0.16 mmol) in DCM (5 mL) was added trifluoroaceic acid (TFA, 1 mL), the reaction mixture was shaken at room temperature for 4 hrs. After the reaction was completed, the resin was filtered off and repeatedly washed with DCM and MeOH and concentrated. After ethylacetate (3 mL) was added to the concentrated mixture, the reaction mixture was subjected to filtration with a strong anion exchange resin (SAX resin) and repeatedly washed with ethylacetate to remove residual trifluoroacetic acid. After the filtrate was subjected to reduced concentration, the concentrate was isolated and purified with a silica gel column chromatography using a solvent mixture of hexane/ethylacetate (4/1, v/v), to obtain a lemon yellow oil of final compound 1 (31.9 mg, Four step overall yields = 53% from loading capacity 0.50 mmol/g). 
